CONVINCE随机试验:高通量血液透析滤过对慢性肾脏病患者生活质量有积极影响
CONVINCE试验在1360例透析依赖的慢性肾脏病患者中比较高通量血液透析滤过(HDF)与高通量血液透析(HD),继发分析显示HDF组健康相关生活质量(HRQoL)下降更慢,认知功能差异最明显。中位观察30个月后,校正死亡差异的联合模型显示HDF组躯体功能、认知功能、疼痛干扰和社会参与下降显著更慢,躯体健康综合评分每年少降0.46单位。
要点
- HDF组HRQoL多个维度下降更慢,认知功能差异最明显。
- 校正死亡差异后,HDF组躯体功能、认知功能、疼痛干扰、社会参与下降显著更慢。
- HDF组躯体健康综合评分较HD组每年少降0.46单位。
核心结论
- 高通量HDF对透析依赖的慢性肾脏病患者生存有益,并对生活质量有中等程度的积极影响,以认知功能最明显。
研究设计与样本
- CONVINCE随机对照试验,1360例透析依赖的慢性肾脏病成人按1:1随机接受高通量HDF(23升或以上)或高通量HD。
- 使用PROMIS工具在随机化前及之后每三个月评估8个HRQoL领域,问卷总应答率84%。
主要发现
- 两组所有HRQoL领域均持续恶化,但HDF组自基线原始评分变化总体更有利,中位观察30个月后总体检验显著。
- 认知功能原始评分变化:HDF组下降-0.95单位(95%CI -2.23至+0.34),HD组下降-3.90单位(95%CI -5.28至-2.52)。
- 校正死亡差异的联合模型显示HDF组躯体功能、认知功能、疼痛干扰和社会参与下降显著更慢。
- HDF组躯体健康综合评分较HD组每年少降0.46单位。
临床怎么用
- 在适合高通量HDF(23升或以上)的透析依赖慢性肾脏病患者中,可考虑HDF以延缓HRQoL下降,尤其是认知功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the CONVINCE trial, the primary analysis demonstrated a survival benefit for patients receiving high-dose hemodiafiltration (HDF) as compared with high-flux hemodialysis (HD). A secondary objective was to evaluate effects on health-related quality of life (HRQoL); assessed in eight domains (physical function, cognitive function, fatigue, sleep disturbance, anxiety, depression, pain interference, social participation) applying instruments from the Patient-Reported Outcome Measurement Information System (PROMIS) before randomization and every three months thereafter. In total 1360 adults with dialysis-dependent chronic kidney disease, eligible to receive high-flux HDF (23 liters or more), were randomized (1:1); 84% response rate to all questionnaires. Both groups reported a continuous deterioration in all HRQoL domains. Overall, raw score changes from baseline were more favorable in the HDF group, resulting in a significant omnibus test after a median observation period of 30 months. Most relevant single raw score differences were reported for cognitive function. Patients receiving HDF reported a decline of -0.95 units (95% confidence interval - 2.23 to +0.34) whereas HD treated patients declined by -3.90 units (-5.28 to - 2.52). A joint model, adjusted for mortality differences, utilizing all quarterly assessments, identified a significantly slower HRQoL decline in physical function, cognitive function, pain interference, and social participation for the HDF group. Their physical health summary score declined -0.46 units/year slower compared to the HD group. Thus, the CONVINCE trial showed a beneficial effect of high-dose hemodiafiltration for survival as well as a moderate positive effect on patients' quality of life, most pronounced with respect to their cognitive function. REGISTRATION: NTR7138 on the International Clinical Trials Registry Platform.
引用
- Rose M, Fischer FH, Liegl G, et al. The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration. Kidney Int. 2024. PMID: 39089577. doi:10.1016/j.kint.2024.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。